← FDA DRUG APPROVALS

FDA ANDA · ANDA206198

OXACILLIN

Sponsor: FRESENIUS KABI USA

APPLICATION
ANDA206198
TYPE
ANDA
ORIGINAL APPROVAL
2020-07-20
LATEST ACTION
2020-07-20
ROUTE
INTRAMUSCULAR, INTRAVENOUS, INJECTION
DOSAGE FORM
INJECTABLE
MARKETING STATUS
Prescription

Products

OXACILLIN SODIUMPrescription
OXACILLIN SODIUM EQ 1GM BASE/VIAL · INJECTABLE · INJECTION
OXACILLIN SODIUMPrescription
OXACILLIN SODIUM EQ 2GM BASE/VIAL · INJECTABLE · INJECTION

Approval history

2020-07-20UNKNOWN · Original · standardAP
VIEW ON DRUGS@FDA ↗

Related on SPEQ

Pharma industryGMP disciplineFDA drug shortagesFDA enforcement & recalls

Source: FDA Drugs@FDA. SPEQ is not affiliated with the FDA; this is a reference view of public FDA data, not medical, legal, or regulatory advice.

Weekly Briefing

Get the Weekly GxP Briefing

Curated regulatory intelligence — enforcement, recalls, guidance, and quality signals — in one practitioner-grade email each week. Free.

Read a past issue →